These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 26572169)

  • 1. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
    Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
    BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.
    Masago K; Fujita S; Hata A; Okuda C; Yoshizumi Y; Kaji R; Katakami N; Hirata Y; Yatabe Y
    Pathol Int; 2018 Mar; 68(3):167-173. PubMed ID: 29341374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
    Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
    Asami K
    Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
    J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.
    Stein MK; Morris L; Sullivan JL; Fenton M; VanderWalde A; Schwartzberg LS; Martin MG
    Med Oncol; 2017 Jul; 34(7):126. PubMed ID: 28573640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
    Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
    Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.